Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim +8 more
wiley +1 more source
Targeting Interferon-Gamma (IFN-γ)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances. [PDF]
Rahaman MM, Wangchuk P, Sarker S.
europepmc +1 more source
Exploring the interactions of Interferon-gamma and polyphenols in colorectal cancer cells [PDF]
Jordan-Mahy, Nikki +3 more
core
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang +14 more
wiley +1 more source
Optimization of a bovine whole-blood cytokine recall assay for the detection of interferon-gamma and interleukin 10 following stimulation with <i>Coxiella burnetii</i> antigens. [PDF]
O'Shannessy L +7 more
europepmc +1 more source
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source
Interferon-gamma 1b-induced gene expression alters neutrophil function in patients with chronic granulomatous disease. [PDF]
Ambruso DR +8 more
europepmc +1 more source
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang +7 more
wiley +1 more source
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao +16 more
wiley +1 more source
A novel non-invasive diagnostic approach based on urine and blood: a cross-sectional study combining lipoarabinomannan antigen and interferon-gamma release assay for active tuberculosis. [PDF]
Cai L +6 more
europepmc +1 more source

